WuXi Biologics Cayman has filed a patent for a genetically modified cell line that produces a recombinant glycoprotein with a mannose-terminated N-glycan. The cell line contains an insertion of less than 600 bp in the coding region of the MGAT1 gene. This invention could potentially improve the production of glycoproteins with specific glycan structures. GlobalData’s report on WuXi Biologics Cayman gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights WuXi Biologics Cayman Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on WuXi Biologics Cayman, Personalized cancer vaccines was a key innovation area identified from patents. WuXi Biologics Cayman's grant share as of September 2023 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Genetically modified cell line producing mannose-terminated glycoprotein

Source: United States Patent and Trademark Office (USPTO). Credit: WuXi Biologics Cayman Inc

A recently filed patent (Publication Number: US20230287378A1) describes a genetically modified cell line that is deficient in a specific gene called MGAT1. The cell line has an insertion of less than 600 base pairs in the coding region of the MGAT1 gene. The patent claims that the cell line can be modified using genome editing technology, such as CRISPR, ZFN, or TALEN. The cell line is preferably an animal cell, specifically a Chinese Hamster Ovary (CHO) cell.

The genetically modified cell line is capable of expressing glycoproteins that contain mannose residues. The patent claims that the cell line can be used to produce recombinant glycoproteins through a method that involves culturing the cell line and recovering the glycoprotein. Another method described in the patent involves introducing a gene encoding the recombinant protein into the cell line, mutating the MGAT1 gene in the cell line, and expressing the recombinant glycoprotein. The mutation of the MGAT1 gene can be achieved using CRISPR technology.

The patent also describes a method for treating a ß-glucocerebrosidase-deficiency-related disease by administering the recombinant glycoprotein produced by the genetically modified cell line to a subject in need. Additionally, the patent includes a pharmaceutical formulation that comprises the recombinant enzyme, a buffer, an osmoregulator, and a surfactant. The formulation has specific ranges for the amounts of each component and a pH range of 5-7.

In summary, the patent describes a genetically modified cell line deficient in the MGAT1 gene, which can be used to produce glycoproteins with mannose residues. The cell line can be modified using genome editing technology and is particularly useful for producing recombinant glycoproteins. The patent also includes methods for treating diseases related to ß-glucocerebrosidase deficiency and a pharmaceutical formulation for delivering the recombinant enzyme.

To know more about GlobalData’s detailed insights on WuXi Biologics Cayman, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies